← brief for 2026-08-19 · Slowing decline

Sodium zirconium cyclosilicate for renin-angiotensin-aldosterone system inhibitor therapy optimization: A systematic review and meta-analysis with meta-regression.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This meta-analysis combined studies of sodium zirconium cyclosilicate, a drug that lowers potassium in the blood. High potassium often forces doctors to cut back on RAAS inhibitors, which are key kidney-protecting medicines. The review found the potassium drug was linked to people staying on their full kidney medicine. Pooling many studies makes this strong evidence, though the exact numbers are not shown here.

Who did this work

Ghukasyan H · Batista da Hora DA · Fatima SR · Abreu Chagas K · Hayrapetyan T · Casas Todolí J · Llopis Sanchis M · Arslan F

Source

Article · PubMed, CKD progression and prevention · 2026 Aug-Sep
https://pubmed.ncbi.nlm.nih.gov/42618199/